Boston Scientific Acquiring Silk Road Medical for $1.16 Billion

Silk Road Medical: Revolutionizing Stroke Prevention and Carotid Artery Disease Treatment

Silk Road Medical specializes in providing minimally invasive procedures for the treatment of carotid artery disease, which is responsible for one-third of all strokes. This condition occurs when the carotid arteries narrow or get blocked due to the buildup of plaque. Traditional treatment options include medical therapy, stent placement, or surgery, but Silk Road Medical offers a cutting-edge alternative called transcarotid artery revascularization (TCAR).

What is Transcarotid Artery Revascularization?

TCAR involves making a small incision in the neck, temporarily reversing blood flow to prevent dislodged plaque from reaching the brain, and placing a stent to stabilize plaque and prevent future strokes. This minimally invasive procedure is clinically proven to offer reduced stroke risk and fewer complications compared to traditional surgery.

Significance of TCAR

Cat Jennings, President of vascular and peripheral interventions at Boston Scientific, describes the TCAR platform developed by Silk Road Medical as a notable advancement in the field of vascular medicine. TCAR has revolutionized stroke prevention and the treatment of carotid artery disease.

Clinical Studies

The TCAR system received FDA approval in 2015 and is backed by multiple clinical studies demonstrating its effectiveness in reducing the risk of stroke and complications. Silk Road Medical’s products are the only devices approved for use in the TCAR procedure. The positive results of these clinical studies make TCAR an attractive option for patients and physicians alike.

The Acquisition by Boston Scientific

Boston Scientific, a medical device company based in Marlborough, Massachusetts, recently agreed to acquire Silk Road Medical. This move will bolster Boston Scientific’s portfolio and pave the way to further innovation in minimally invasive vascular procedures. The transaction is expected to close in the second half of 2024, subject to customary closing procedures.

Projected Revenue

Silk Road Medical projects net revenue of approximately $194-198 million in 2024, reflecting a 10-12% increase from the previous year. This growth is attributable to the company’s innovative and effective clinical solutions that meet the needs of patients and healthcare providers.

Boston Scientific’s Acquisition of Axonics Inc.

Boston Scientific’s recent acquisition of Axonics Inc. is also a significant development poised to bolster the company’s urology portfolio. Axonics Inc. is a major player in the development of innovative devices for urinary and bowel dysfunction treatments. This acquisition is worth $3.7 billion and signals Boston Scientific’s commitment to expanding its portfolio in order to provide innovative and effective medical solutions.

Conclusion

The acquisition of Silk Road Medical by Boston Scientific is a significant development that demonstrates the growing interest and investment in minimally invasive vascular procedures. TCAR, in particular, offers a promising alternative to traditional surgical options for the treatment of carotid artery disease and reducing the risk of stroke. With the acquisition of Silk Road Medical and Axonics Inc., Boston Scientific is well-positioned to continue innovating and expanding its portfolio in order to meet the needs of patients and healthcare providers with the most effective and innovative clinical solutions.

Originally Post From https://www.dotmed.com/news/story/63202